Your browser doesn't support javascript.
loading
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trial.
Ali, Shaukat; Shalim, Elisha; Farhan, Farah; Anjum, Fatima; Ali, Ayesha; Uddin, Syed Muneeb; Shahab, Faisal; Haider, Mustafa; Ahmed, Iqra; Ali, Mir Rashid; Khan, Sadaf; Rao, Sadia; Guriro, Kabeer; Elahi, Saud; Ali, Muhammad; Mushtaq, Tehreem; Sayeed, Muneeba Ahsan; Muhaymin, Sheikh Muhammad; Luxmi, Shoba; Qureshi, Saeed.
Afiliación
  • Ali S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan. ali.shaukat@duhs.edu.pk.
  • Shalim E; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Farhan F; Department of Biotechnology, University of Karachi, Karachi, Pakistan.
  • Anjum F; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Ali A; Dow Research Institute Of Bio-Technology And Bio-Sciences (DRIBBS), Dow University of Health Sciences, Karachi, Pakistan.
  • Uddin SM; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Shahab F; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Haider M; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Ahmed I; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Ali MR; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Khan S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Rao S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Guriro K; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Elahi S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Ali M; Department of Biotechnology, University of Karachi, Karachi, Pakistan.
  • Mushtaq T; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Sayeed MA; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Muhaymin SM; Sindh Infectious Disease Hospital and Research Center, Karachi, Pakistan.
  • Luxmi S; Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan.
  • Saifullah; Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan.
  • Qureshi S; Department of Biotechnology, University of Karachi, Karachi, Pakistan.
Trials ; 23(1): 932, 2022 Nov 08.
Article en En | MEDLINE | ID: mdl-36348476
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neumonía Viral / Infecciones por Coronavirus / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: Pakistán
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neumonía Viral / Infecciones por Coronavirus / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2022 Tipo del documento: Article País de afiliación: Pakistán